Clinical, histopathological and immunohistochemical characterization of canine indolent lymphoma

Veterinary and Comparative Oncology

Volumn 11, Issue 4, 2013, Pages 272-286

  Flood Knapik, K E ^a   Durham, A C ^a   Gregor, T P ^a   Sanchez M D ^a   Durney, M E ^a   Sorenmo, K U ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Canine; Indolent; Ki67; Low grade; Lymphoma; Marginal zone; T zone

Indexed keywords

CANIS FAMILIARIS;

ANTINEOPLASTIC AGENT; CD3 ANTIGEN; CD79 ANTIGEN; KI 67 ANTIGEN; MARGINAL ZONE; MULTIDRUG RESISTANCE PROTEIN; TUMOR MARKER;

ANIMAL; ANIMAL DISEASE; ARTICLE; CANINE; COHORT ANALYSIS; DOG; DOG DISEASE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; INDOLENT; KI67; LOW-GRADE; LYMPHOMA; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; RETROSPECTIVE STUDY; SURVIVAL; T-ZONE;

CANINE; INDOLENT; KI67; LOW-GRADE; LYMPHOMA; MARGINAL ZONE; T-ZONE;

ANIMALS; ANTIGENS, CD3; ANTIGENS, CD79; ANTINEOPLASTIC AGENTS; COHORT STUDIES; DOG DISEASES; DOGS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LYMPHOMA; MALE; P-GLYCOPROTEIN; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84886640867     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2011.00317.x     Document Type: Article

References (43)

1. Bergman P, Ogilvie G and Powers B. Monoclonal antibody C219 immunohistochemistry against P-glycoprotein: sequential analysis and predictive ability in dogs with lymphoma. Journal of Veterinary Internal Medicine 1996; 10: 354-359.
2. Zemann BI, Moore AS, Rand WM, Mason G, Ruslander DM, Frimberger AE, Wood CA, L'Heureux DA, Gliatto J and Cotter SM.A combination chemotherapy protocol (VELCAP-L) for dogs with lymphoma. Journal of Veterinary Internal Medicine 1998; 12: 465-470.
3. Myers NC, Moore AS, Rand WM, Gliatto J and Cotter SM. Evaluation of a multidrug chemotherapy protocol (ACOPA II) in dogs with lymphoma. Journal of Veterinary Internal Medicine 1997; 11: 333-339.
4. Garrett LD, Thamm DH, Chun R, Dudley R and Vail DM. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. Journal of Veterinary Internal Medicine 2002; 16: 704-709.
5. Hosoya K, Kisseberth WC, Lord LK, Alvarez FJ, Lara-Garcia A, Kosarek CE, London CA, and Couto CG. Comparison of COAP and UW-19 protocols for dogs with multicentric lymphoma. Journal of Veterinary Internal Medicine 2007; 21: 1355-1363.
6. Sorenmo K, Overley B, Krick E, Ferrara T, LaBlanc A and Shofer F. Outcome and toxicity associated with a dose-intensified, maintenance-free CHOP-based chemotherapy protocol in canine lymphoma: 130 cases. Veterinary and Comparative Oncology 2010; 8: 196-208.
7. th edn., Edinburgh, Elsevier Saunders, 2007.
8. Keller ET, MacEwen EG, Rosenthal RC, Helfand SC and Fox LE. Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma. Journal of Veterinary Internal Medicine 1993; 7: 289-295.
9. Fournel-Fleury C, Magnol J, Bricaire P, Marchal T, Chabanne L, Delverdier A, Bryon PA and Felman P. Cytohistological and immunological classification of canine malignant lymphomas: comparison with human non-hodgkin's lymphomas. Journal of Comparative Pathology 1997; 117: 35-59.
10. Ponce F, Marhal T, Magnol J, Turinelli V, Ledieu D, Bonnefont C, Pastor M, Delignette ML and Fournel-Fleury C. A morphological study of 608 cases of canine malignant lymphoma in France with a focus on comparative similarities between canine and human lymphoma morphology. Veterinary Pathology 2010; 43: 414-433.
11. Carter RF, Valli VE and Lumsden JH. The cytology, histology and prevalence of cell types in canine lymphoma classified according to the National Cancer Institute Working Formulation. Canadian Journal of Veterinary Research 1986; 50: 154-164.
12. st edn., Ames, Blackwell Publishing, 2007.
13. Valli V. Veterinary pathologists achieve 80% agreement in application of WHO diagnoses to canine lymphoma. Cancer Therapy 2008; 6: 221-226.
14. Valli V and Jacobs R. Histological Classification of Hematopoietic Tumors of Domestic Animals. Washington, D.C., Armed Forces Institute of Pathology in cooperation with the American Registry of Pathology and the World Health Organization Collaborating Center for Comparative Oncology, 2002.
15. Valli V, Vernau W, Lorimier LD, Graham P and Moore PF. Canine indolent nodular lymphoma. Veterinary Pathology 2006; 43: 241-256.
16. Fournel-Fleury C, Magnol J, Chabanne L, Ghernati I, Marchal T, Bonnefond C, Bryon PA, and Felman P. Growth fractions in canine non-Hodgkin's lymphomas as determined in situ by the expression of the Ki-67 antigen. Journal of Comparative Pathology 1997; 117: 61-72.
17. Bauer N, Zervos D and Moritz A. Argyrophilic nuclear organizing regions and Ki67 equally reflect proliferation in fine needle aspirates of normal, hyperplastic, inflamed and neoplastic canine lymph nodes (n = 101). Journal of Veterinary Internal Medicine 2007; 21: 928-935.
18. Kiupel M, Teske E and Bostock D. Prognostic factors for treated canine malignant lymphoma. Veterinary Pathology 1999; 36: 292-300.
19. Hall P, Richards M, Gregory W, d'Ardenne A, Lister T and Stansfeld A. The prognostic value of Ki67 immunostaining in non-Hodgkin's lymphoma. The Journal of Pathology 1988; 154: 223-235.
20. Miller T, Grogan T, Dahlberg S, Spier C, Braziel R, Banks PM, Foucar K, Kjeldsberg CR, Levy N, Nathwani BN, Schnitzer B, Tubbs RR, Gaynor ER and Fisher RI. Prognostic significance of the Ki-67-associated proliferation antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. Blood 1994; 83: 1460-1466.
21. Ginn P. Immunohistochemical detection of p-glycoprotein in formalin-fixed and paraffin-embedded normal and neoplastic canine tissues. Journal of Veterinary Pathology 1996; 33: 533-541.
22. Lee JJ, Hughes CS, Fine RL and Page RL. P-glycoprotein expression in canine lymphoma: a relevant, intermediate model of multidrug resistance. Cancer 1996; 77: 1892-1898.
23. Moore AS, Leveille CR, Reimann KA, Shu H and Arias IM. The expression of P-glycoprotein in canine lymphoma and its association with multidrug resistance. Cancer Investigation 1995; 13: 475-479.
24. Valli V, San Myint M, Barthel A, Bienzle D, Caswell J, Colbatzky F, Durham A, Ehrhart EJ, Johnson Y, Jones C, Kiupel M, Labelle P, Lester S, Miller M, Moore P, Moroff S, Roccabianca P, Ramos-Vara J, Ross A, Scase T, Tvedten H and Vernau W. Classification of canine malignant lymphomas according to the World Health Organization criteria. Veterinary Pathology 2011; 48: 198-211.
25. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J and Vardiman JW. WHO Classifcation of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, International Agency for Research on Cancer, 2008.
26. O'Leary HM and Savage KJ. Update on the World Health Organization classification of peripheral T-cell lymphomas. Current Hematologic Malignancy Reports 2009; 4: 227-235.
27. Macon WR, Williams ME, Greer JP and Cousar JB. Paracortical nodular T-cell lymphoma. Identification of an unusual variant of peripheral T-cell lymphoma. American Journal of Surgical Pathology 1995; 19: 297-303.
28. Montalban C, Obeso G, Gallego A, Castrillo JM, Bellas C and Rivas C. Peripheral T-cell lymphoma: a clinicopathological study of 41 cases and evaluation of the prognostic significance of the updated Kiel classification. Histopathology 1993; 22: 303-310.
29. Rudiger T, Ichinohasama R, Ott MM, Muller-Deubert S, Miura I, Ott G and Müller-Hermelink HK. Peripheral T-cell lymphoma with distinct perifollicular growth pattern: a distinct subtype of T-cell lymphoma? American Journal of Surgical Pathology 2000; 24: 117-122.
30. Savage KJ, Ferreri AJ, Zinzani PL and Pileri SA. Peripheral T-cell lymphoma - Not otherwise specified. Critical Reviews in Oncology/Hematology 2010.
31. Maes B and De Wolf-Peeters C. Marginal zone cell lymphoma - an update on recent advances. Histopathology 2002; 40: 117-26.
32. Berger F, Felman P, Thieblemont C, Pradier T, Baseggio L, Bryon PA, Salles G, Callet-Bauchu E and Coiffier B. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood 2000; 95: 1950-1956.
33. DeVita VT, Lawrence TS and Rosenberg SA. DeVIta, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology, 8th edn., Philadelphia, Lippincott Williams and Wilkins, a Woldters Kluwer Business, 2008.
34. Arcaini L, Paulli M, Burcheri S, Rossi A, Spina M, Passamonti F, Lucioni M, Motta T, Canzonieri V, Montanari M, Bonoldi E, Gallamini A, Uziel L, Crugnola M, Ramponi A, Montanari F, Pascutto C, Morra E and Lazzarino M. Primary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare disease. British Journal of Haematology 2007; 136: 301-304.
35. Uherova P, Ross C, Finn W, Singleton T, Kansal R and Schnitzer B. Peripheral T-cell lymphoma mimicking marginal zone B-cell lymphoma. Modern Pathology 2002; 15: 420-425.
36. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89: 3909-3918.
37. Williams MJ, Avery AC, Lana SE, Hillers KR, Bachand AM and Avery PR. Canine lymphoproliferative disease characterized by lymphocytosis: immunophenotypic markers of prognosis. Journal of Veterinary Internal Medicine 2008; 22: 596-601.
38. Barriga OO, al-Khalidi NW, Martin S and Wyman M. Evidence of immunosuppression by Demodex canis. Journal of Veterinary Immunology and Immunopathology 1992; 32: 37-46.
39. Sarker P, Mukherjee J, Ghosh A, Bhattacharjee M, Mahato S, Chakraborty A, Mondal M, Banerjee C and Chaudhuri S. A comparative analysis of immunorestoration and recovery with conventional and immunotherapeutic protocols in canine generalized demodicosis: a newer insigt of immunotherapeutic efficacy of T11TS. Immunological Investigations 2004; 33: 45368.
40. Seyhan ME, Karincaoglu Y, Bayram N, Aycan O and Kuku I. Density of Demodex folliculorum in haematological malignancies. Journal of International Medical Research 2004; 32: 411-415.
41. Herron MD, O'Reilly MA and Vanderhooft SL. Refractory Demodex folliculitis in five children with acute lymphoblastic leukemia. Pediatric Dermatology 2005; 22: 407-411.
42. Stefanello D, Valenti P, Zini E, Comazzi S, Gelain ME, Roccabianca P, Avallone G, Caniatti M and Marconato L. Splenic marginal zone lymphoma in 5 dogs (2001-2008). Journal of Veterinary Internal Medicine 2011; 25: 90-93.
43. Mazloom A, Medeiros LJ, McLaughlin PW, Reed V, Cabanillas FF, Fayad LE, Pro B, Gonzalez G, Iyengar P, Urbauer DL, Dabaja BS. Marginal zone lymphomas: factors that affect the final outcome. Cancer 2010; 116: 4291-4298.